Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
SAN DIEGO, May 02, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Wednesday, May 9, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | May 9, 2018 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 3189378 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
| Company Contact: Patricia Bitar Chief Financial Officer (858) 550-0780 ext. 223 [email protected] | Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected] | |
